Systemic inflammation response index as a predictor of 3-month functional outcomes in acute ischemic stroke patients following intravenous thrombolysis.

BACKGROUND

Inflammation is a critical factor in the pathogenesis of acute ischemic stroke (AIS). The systemic inflammation response index (SIRI), which combines three inflammatory markers, serves as a comprehensive, accessible, and cost-effective tool for assessing inflammation. However, the potential of SIRI to predict the 3-month outcomes of AIS patients following intravenous thrombolysis (IVT) has not been fully explored. Given the urgency of improving patient prognostication and treatment strategies, this study aims to assess the predictive value of SIRI for AIS prognosis at the 3-month mark, providing insights that could enhance clinical decision-making and guide future therapeutic approaches.

METHODS

AIS patients who received IVT from December 2020 to June 2024 were enrolled. The Modified Rankin Scale (mRS) was utilized to evaluate clinical outcomes. Propensity score matching (PSM) and logistic regression analysis were performed to investigate the association between SIRI and the 3-month prognosis in AIS patients.

RESULTS

A total of 559 AIS patients were enrolled in the study, with 433 (77.5 %) experiencing poor outcome. Among the 83 matched patient pairs following propensity score matching (PSM), a significant association was observed between the SIRI and clinical outcomes (OR, 2.27; 95 % CI, 1.42-3.65; p < 0.001). The optimal cutoff value for predicting outcomes was identified as a SIRI level of 0.856, achieving sensitivity and specificity of 84.1 % and 51.7 %, respectively.

CONCLUSIONS

Elevated SIRI levels are indicative of an increased likelihood of poor outcomes following IVT in AIS patients, suggesting that SIRI could serve as a valuable prognostic biomarker for patient recovery.